Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
United States
(484) 875-3192
https://www.annovisbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 6
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, CEO, President & Executive Director | 965.6k | N/D | 1951 |
| Mr. Henry Hagopian III, M.B.A. | Chief Financial Officer | 510.05k | N/D | 1968 |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development | N/D | N/D | N/D |
| Ms. Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations | N/D | N/D | N/D |
| Ms. Melissa Gaines | Senior Vice President of Clinical Operations | N/D | N/D | N/D |
Descripción
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Annovis Bio, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
